Lilly's Q4 Revenue Beats Estimates, Announces $8.9B in Acquisitions, Advances Key Drug Trials
LLY sits 39% above its 52-week low of $623.78.
Summary
Eli Lilly reported robust Q4 revenue of $19.29 billion, surpassing estimates by 7.4% with a 42.6% year-over-year increase. Concurrently, the company announced significant strategic acquisitions totaling approximately $8.9 billion, including Centessa for $6.3 billion, CrossBridge for $300 million, and Ajax Therapeutics for up to $2.3 billion, all aimed at bolstering its R&D pipeline across various therapeutic areas. Additionally, early data for eloralintide showed promising efficacy for weight loss, and initial commercial prescription data for Foundayo was released, showing ~3,700 prescriptions in its first full week. This comprehensive update follows recent positive news regarding Foundayo's trial results and regulatory status, now providing early commercialization metrics and substantial pipeline expansion. While the stock experienced an 11.9% drop following the report, suggesting market concerns possibly related to guidance or other factors not detailed, the underlying operational performance and strategic moves are highly material. Investors will closely monitor the integration of the acquired assets, further clinical trial data for eloralintide, and the sales trajectory of Foundayo.
At the time of this announcement, LLY was trading at $869.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $820.4B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.